New hope for pancreatic cancer: immune-boosting drug combo enters trial
NCT ID NCT06050317
First seen May 03, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and radiation can help people with pancreatic cancer that cannot be removed by surgery. The trial will enroll 25 adults who have not had prior treatment for their cancer. Researchers will measure how long the cancer stays under control and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology, Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 0531, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.